biologic

Novolog Mix 70/30

insulin aspart protamine and insulin aspart

Loss of exclusivityNovember 2013projected — 12-year biologic exclusivity estimate
CompanyNovo Nordisk Inc.

Drug detail

Brand nameNovolog Mix 70/30
Active ingredientinsulin aspart protamine and insulin aspart
Strength700UNITS/10ML (70UNITS/ML); 300UNITS/10ML (30UNITS/ML)
Dosage formInjectable Suspension
RouteSubcutaneous
ModalityBiologic
FDA approvalNovember 2001
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Novolog Mix 70/30 patent cliff — loss of exclusivity November 2013 | CliffBio